Last reviewed · How we verify
Exenatide once weekly (EQW )
Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion in response to elevated blood glucose and slows gastric emptying to reduce postprandial glucose levels.
Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion in response to elevated blood glucose and slows gastric emptying to reduce postprandial glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Exenatide once weekly (EQW ) |
|---|---|
| Also known as | • Bydureon, • Long acting glucagon like peptide 1 (GLP1) agonist |
| Sponsor | Woman's |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R (GLP-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Exenatide mimics glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells. It also inhibits glucagon secretion when blood glucose is elevated and delays gastric emptying, which collectively reduce postprandial blood glucose excursions. The once-weekly formulation (EQW) uses extended-release microsphere technology to provide sustained drug delivery over seven days.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Injection site reactions
Key clinical trials
- Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes (PHASE3)
- EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) (PHASE3)
- Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients (PHASE4)
- Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide once weekly (EQW ) CI brief — competitive landscape report
- Exenatide once weekly (EQW ) updates RSS · CI watch RSS
- Woman's portfolio CI